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Abstract
There is a paucity of literature describing metabolic and histological data in adult-onset autoimmune diabetes. This
subgroup of diabetes mellitus affects at least 5% of clinically diagnosed type 2 diabetic patients (T2DM) and it is termed
Latent Autoimmune Diabetes in Adults (LADA). We evaluated indexes of insulin secretion, metabolic assessment, and
pancreatic pathology in clinically diagnosed T2DM patients with and without the presence of humoral islet autoimmunity
(Ab). A total of 18 patients with at least 5-year duration of clinically diagnosed T2DM were evaluated in this study. In those
subjects we assessed acute insulin responses to arginine, a glucose clamp study, whole-body fat mass and fat-free mass. We
have also analyzed the pancreatic pathology of 15 T2DM and 43 control cadaveric donors, using pancreatic tissue obtained
from all the T2DM organ donors available from the nPOD network through December 31, 2013. The presence of islet Ab
correlated with severely impaired b-cell function as demonstrated by remarkably low acute insulin response to arginine
(AIR) when compared to that of the Ab negative group. Glucose clamp studies indicated that both Ab positive and Ab
negative patients exhibited peripheral insulin resistance in a similar fashion. Pathology data from T2DM donors with Ab or
the autoimmune diabetes associated DR3/DR4 allelic class II combination showed reduction in beta cell mass as well as
presence of autoimmune-associated pattern A pathology in subjects with either islet autoantibodies or the DR3/DR4
genotype. In conclusion, we provide compelling evidence indicating that islet Ab positive long-term T2DM patients exhibit
profound impairment of insulin secretion as well as reduced beta cell mass seemingly determined by an immune-mediated
injury of pancreatic b-cells. Deciphering the mechanisms underlying beta cell destruction in this subset of diabetic patients
may lead to the development of novel immunologic therapies aimed at halting the disease progression in its early stage.
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Introduction
Type 2 diabetes mellitus (T2DM) represents a group of
heterogeneous metabolic diseases encompassing a wide variety of
pathogenetic mechanisms ranging from abnormalities related to
glucose-stimulated insulin secretion [1,2], insulin resistance [3,4],
endoplasmic reticulum stress-induced b cell apoptosis [5] and
inflammatory-mediated lesions of the target organ [6–10].
Previous studies have shown that 5–10% of patients with T2DM
exhibit autoantibodies against the islet antigen glutamic acid
decarboxylase, 65 kDa isoform, (GAD), one of the well-recognized
markers of islet cell autoimmunity in Type 1 diabetes (T1DM).
This subgroup of diabetes mellitus affects at least 5% of clinically
diagnosed type 2 diabetic patients (T2DM) [11–16]. These
patients are commonly classified as having Latent Autoimmune
Diabetes in Adults (LADA) [17–20]. This group is characterized
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by progression to insulin-requiring diabetes, lower C-peptide levels
and usually lower body mass index (BMI) in younger subjects (e.g.
45 years of age) [12,19,21].
Whether LADA represents a distinct group from T1DM or it is
just the same entity presenting later in life is still under debate.
Recent literature suggests this group is distinct from T1DM
genetically and immunologically [22]. Detailed metabolic and
histologic studies in LADA patients are still lacking. We have
previously reported two heterogeneous patterns of beta cell
pathology in Diabetes Mellitus namely pattern A (characterized
by the presence of pseudo-atrophic islets, i.e. islets completely
devoid of insulin positive cells) and pattern B (characterized by the
absence of pseudo-atrophic islets) [23]. Pattern A is strongly
associates with autoimmune Type 1 diabetes (T1a) while pattern B
is usually seen in non-autoimmune Type 1 diabetes (T1b).
In this study we evaluated patients affected by LADA and
compared to antibody negative T2DM of comparable BMI, age
and duration of diabetes. For the first time, our analysis included
beta cell assessment through arginine stimulation and peripheral
insulin sensitivity through a euglycemic clamp in addition to the
assessment of the pathology from T2DM adult onset organ donors
with and without islet autoimmunity from the unique nPOD
collection. Our observations demonstrate that T2DM patients
with evidence for islet autoimmunity exhibit unique metabolic and
histological characteristics including insulin deficiency and pattern
A pancreatic pathology.
Material and Methods
Human Subjects
Type 2 diabetic patients were recruited in the Metabolism,
Endocrinology & Diabetes (MEND) clinic at University of
Michigan. The protocol was approved by the University of
Michigan Institutional Review Board. Participants provided their
written informed consent to participate in this study. A total of 18
subjects with clinically diagnosed T2DM participated in this study.
Seventeen out of 18 subjects were of Caucasian and one of African
American descent. Inclusion criteria included: 40 years of age or
older, type 2 was diagnosed according to standard National
Diabetes Data Group criteria [24].
The participants recruited in the present study were treated with
insulin, metformin or a combination of both. Patients on insulin
had duration of clinically diagnosed T2DM for at least 5 years.
Exclusion criteria included: Onset of diabetes before the age of 40,
first degree relatives of T1DM patients, pregnancy, concurrent
illness and/or disease that limits life expectance or lead to
immunosuppressive or immunomodulatory therapy during the
time of the study, history of liver disease, substance abuse and
deemed unlikely to comply with the protocol.
Participants were categorized in the following three groups:
antibody negative clinically diagnosed T2DM treated with
metformin only, antibody negative on insulin6metformin, anti-
body positive on insulin6metformin. In terms of therapy, 2 of the
6 subjects in the antibody negative group on insulin were also
treated with metformin. In the antibody positive insulin-dependent
group, 3 of 7 were also treated with metformin. All of the subjects
who were treated with insulin at the time of testing used at least 6
months of oral hypoglycemic agents prior to transitioning to
insulin therapy. All participants were evaluated for the presence of
GAD65, IA-2 and ZnT8 antibodies. Six out of those 18
participants were positive for GAD65 antibodies: Of those
GAD65 Ab positive patients, 2 were also positive for IA-2 and 3
for ZnT8 antibodies. One of these subjects was positive for IA-2
Ab alone.
As shown in Table 1, there was no significant difference in
terms of age, body mass index (BMI) or HbA1c level between the
three groups. In terms of HbA1c level, the majority of the subjects
were in the 6-8% range, except for one participant in the antibody
positive group (HbA1c of 11.4%). The best glycemic control trend
was seen in the metformin only group both in terms of HbA1c
(HbA1c 7.1% vs. 7.6% for the antibody negative on insulin group)
and in terms of the fasting glucose (133 vs.175 mg/dl). The
metformin only group had a statistically significant shorter
duration of diabetes (3.8 vs. 16.2 years for the antibody negative
group on insulin therapy, which has the longest duration of
diabetes).
Organ donors
Organ donors were procured through the JDRF sponsored
network of pancreatic organ donors with diabetes (nPOD)
initiative [25]. Pancreatic specimens were obtained from all the
donors, originally diagnosed with T2DM, available from nPOD
through December 31, 2013 [23,25]. Pancreatic tissue sections
were prepared as previously described [23]. For this study, we
analyzed the pancreatic pathology of 15 T2DM and 43 controls.
This group consisted of all T2DM donors (not treated with
incretins) and all control donors (with pancreatic weight data)
available in the nPOD collection as 12/31/2013. Three of the
T2DM donors were African American, one was Asian-American,
eight were Caucasian and three were Hispanic. The mean age of
onset in this group was 32 years (median 26.3 years, range 15.8 to
60.3 years), while the mean age at death was 42.8 years (median
42.8 years, range = 18.8 to 76.3 years) (Table 2 summarizes the
demographic and immunological features of the T2DM antibody
positive donors).
The control group was composed of five African-American,
thirty- five Caucasian and three Hispanic donors. Twenty-five of
these donors were male and thirteen were female. The mean age
at death in this group was 28.9 years (median 22.1 years, range 2.2
– 45.9).
Islet Autoantibody testing
Serum samples were assayed for autoantibodies directed to
GAD65, IA-2 and ZnT8 as previously described (15, 16). The
GAD65 construct was donated by Dr. Lernmark, while the IA-2
construct (ICA512bdc amino acid 267–556; 630–979) was
donated by Dr. Eisenbarth. The results were expressed as an
index (index = [cpm – negative control cpm]/[positive control
cpm – negative control cpm]). Previously evaluated serum samples
which were highly reactive for either IA-2 or GAD65 were utilized
as positive controls, while pooled sera from non-diabetic individ-
uals was utilized as a negative experimental control.
Additional IA-2 constructs were utilized in the detection of IA-2
autoantibodies. Dr. E. Bonifacio donated the IA-2ic construct
(amino acids 601-979), while a full length IA-2 construct was also
donated by Dr. Eisenbarth (amino acids 1–979). The ZnT8
construct was kindly donated by Dr. Hutton. GAD65 and IA-2
assays have been utilized repeatedly in proficiency workshops.
Proficiency workshop results organized by the University of
Florida, Gainesville (1995, 1996 and 1997), and the Diabetes
Autoantibody Standardization Program (DASP, 2000, 2003, 2005,
2007, 2010), organized by WHO were as follows: 76–100%
sensitivity, 90–100% specificity (100% specificity 3 times), and
100% validity for GAD65 and ICA512bdc autoantibodies; 48–
84% sensitivity, 98–100% specificity, 87.5% validity and 91.6%
consistency in the 1996, 2000 and 2003, 2005, 2007 and 2010. IA-
2 full length and IA-2ic autoantibodies achieved ratings of 68%,
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66% sensitivity and 98%, 99% specificity respectively in the 2007
DASP workshop.
HLA Genotyping
HLA DR typing of organ donors was kindly provided by nPOD
as previously reported [23,26].
Quantification of pancreatic beta cell mass
For each case, pancreatic beta cell mass (BCM) was quantified
using computer assisted morphometric analysis of all available
insulin stained sections from the head, body and tail of the
pancreas. Briefly the insulin stained area was quantified with
ImageProplus (Media Cybernetics, Rockville, MD) and expressed
Table 1. Clinical characteristics. All of the blood sampling was performed under fasting conditions.
Antibody negative
(metformin)
Antibody negative (insulin ±
metformin)
Antibody positive** (insulin ±
metformin)
Age (years) 52.87 (42–68) 55.8 (42–69) 55 (42–68)
Gender (M/F) 2/3 2/4 3/4
Diabetes duration (years) 3.8 (2–6) 16.2 (7–21) 12.8 (6.5–20)
Metformin use 5/5 2/6 3/7
HbA1c (%) 7.1 (6.5–7.5) 7.6 (6.2–9.5) 8.5 (7–11.4)
Weight (kg) 77.2 (69.4–86.6) 87.6 (76.7–103.4) 81.6 (63.8-99)
BMI (kg/m2) 27.6 (26–29.6) 31.7 (25.5–36.2) 32 (26.9–47)
Fat (%) 35.2 (29.8–39.7) 36.7 (18–46.7) 35.7 (24.9–47.6)
Central fat (g) 2853 (2300–3168) 3580 (1538–5317) 2933 (1875–4027)
Central fat (%) 11.1 (8.5–12.7) 12.3 (9.4–13.5) 10.9 (8.5–14.2)
HDL (mg/dL) 54.7 (45.8–62) 41 (30–45) * 74 (56–119) *
TG (mg/dL) 87.2 (38–137) 107 (57–144) 62 (31–163)
FFA (mg/dL) 0.93 (0.78–1.00) 1.0 (0.47–1.44) 0.7 (0.36–0.88)
Glucose (mg/dL) 133 (97–161) 175 (93–234) 204 (121–276)
C-peptide (ng/mL) 2 (1.3–3.5) 2.73 (1.4–4.4) * 0.45 (0–0.6) *
Pro-insulin (pmol/L) 19 (9.5–26) 32.17 (13–95) * 9.2 (0–19) *
Adiponectin (ng/mL) 7944 (4818–12848) 8819 (4295–12410) 15877 (7380–22118)
CRP (mg/L) 1.9 (0.7–3.4) 2.3(0.5–4.5) 3.45 (0.2–8.7)
* = p,0.05 (antibody negative (insulin6 metformin) vs antibody positive (insulin6 metformin)).
**Antibody Positive Group: 6 out of 7 patients were positive for GAD65 Ab. Of those 6 GAD65 Ab positives, 2 were also positive for IA-2 and 3 for ZnT8 Ab. One of these
subjects was positive for IA-2 Ab alone. Antibody titer: 3 GAD65 Ab positive 3rd tertile; 2 IA-2 Ab positive 3rd tertile.
doi:10.1371/journal.pone.0106537.t001
Table 2. Demographic and immunological characteristics of clinically diagnosed T2DM cadaveric donors captured through the
nPOD network.
nPOD ID # Gender Age at death (years) DM duration (years) Ethnicity AA status HLA DR
6028 M 33.2 17.0 AA N DR6;DR6
6037 M 76.3 50.0 CA N DR4;DR3
6059 M 18.8 0.2 HI N DR7;DR8
6108 M 57.9 2.0 ASA N DR15;DR15
6110 F 20.7 0.0 AA N DR3;DR2
6114 M 42.8 2.0 CA N DR7;DR2
6124 F 63.3 3.0 CA N DR4;DR2
6127 F 44.8 10.0 CA N DR4;DR3
6133 F 45.80 20.0 CA N DR10;DR2
6139 F 37.2 1.5 HI N DR4;DR2
6142 F 29.8 14.2 HI P DR6;DR1
6149 F 39.3 16.0 AA P DR9;DR2
6175 M 42.9 12.0 CA N DR3;DR3
6191 F 62.0 10.0 CA N DR4;DR7
6203 M 27.6 5.0 CA N DR11;DR11
AA: African American donors, AS: Asian-American donors, CA: Caucasian donors, HI: Hispanic donors.
doi:10.1371/journal.pone.0106537.t002
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as ratio to the total pancreatic area. The average ratio between
insulin stained area and total areas was multiplied by the
pancreatic weight in gms thus yielding the estimated BCM in
gms. The mean BCM of controls was utilized to expressed the
BCM of each case in relation to controls with the formula: BCM
case = (estimated BCM case/mean estimated BCM of controls)
multiplied by 100.
Islet function testing
The response to arginine, a potent insulin secretagogue, was
utilized to evaluate b-cell function, according to well-established
protocols [2]. Briefly, islet function was evaluated by measurement
of acute insulin responses (AIR) to arginine at three glycemic levels
(150, 250 and 500 mg/dL). After baseline samples were obtained
for measurement of glucose, C-peptide, proinsulin, the acute
insulin response to a maximally stimulating dose of arginine HCl
(10% Arginine Hydrochloride, Pfizer, Lake Forest, IL) was
measured. These responses were calculated from samples drawn
2, 3, 4, 5, 7 and 10 min. after this dose and all subsequent doses of
arginine. Next, a variable rate infusion of 20% dextrose was
administered to raise and maintain the plasma glucose level.
Thirty minutes after the glucose clamp begins, prestimulus samples
were again obtained and AIRs to a pulse of arginine was
measured. The AIR to arginine at the highest glucose level
(500 mg/dL) was defined as AIRmax.
The C-peptide area under the curve (AUC) over the 10-min
interval was estimated for each subject according to previously
published protocols [27]. Disposition index (DI) is calculated as
glucose infusion rate divided by the measured mean insulin
concentration during the second hour of the clamp during the
glucose clamp times AIRmax. DI provides an indirect assessment of
whether insulin secretion is appropriate for the level of insulin
resistance (b-cell compensation for insulin resistance or b-cell
function) [28].
Glucose Clamp Studies
Glucose clamp studies were performed and this is regarded as a
methodology for the determination of insulin sensitivity (18).
Volunteers held metformin and long acting insulin 48 hours and
24 hours prior to the admission respectively. The glucose clamp
study was started following administration of insulin bolus of
240 milliunits/m2/min for 5 minutes followed by insulin infusion
of 80 milliunits/m2/min.
Plasma glucose levels were measured at 5 minute intervals and
maintained at a target value of 90 mg/dl by an adjustable infusion
of 20% dextrose, and the exact concentration of the infusion was
measured prior to each study. Glucose infusion rates (GIR) were
recorded at 5 minute intervals. Once steady-state conditions were
achieved, rates of exogenous glucose infusion, equal rates of
glucose disposal. Thus, GIR provides a quantitative measure of
insulin-stimulated glucose metabolism. Plasma samples to deter-
mine glucose and insulin concentrations were drawn at t =25, 0,
60, 120, 170, 180 min. At t = 180 min, all infusions were stopped
with the exception of the 20% glucose. Plasma glucose was
checked for at least 30 min. after glucose infusion was stopped.
Body Composition Studies
Whole-body fat mass (FM) and fat-free mass (FFM) was assessed
by Dual-energy X-ray Absorptiometry (DEXA) according to
standard protocols [29]. Standing height and weight was checked
in each participant, and the BMI was calculated as weight (kg)/
height (m2). Additional image analysis was done for regional
analysis of body composition.
Statistical Analysis
Non-parametric Friedman test was used to compare acute
insulin response. p values,0.05 were deemed statistically signif-
icant. The chi square test was utilized to compare proportions and
determine a statistically significant association between two
variables. Fisher’s exact test was applied if any expected cell value
in a 262 table was less than 5. Wilcoxon scores (rank sums) were
applied for variable C-peptide AUC during the arginine test. Non-
parameteric Friedman test was used for the comparisons of AIR
among the Ab +, Ab- on insulin, Ab- on metformin groups. DI and
GIR values between groups were compared using the Mann-
Whitney test. Pearson Correlation was used to determine the
degree of correlation between two variables. Data were analyzed
using SAS 9.2 (SAS Institute Inc. Cary, NC) IBM SPSS 21 (SPSS
Chicago, Ill., USA) and PROC StatXact for SAS, version 8 (Cytel
Inc., Cambridge, MA 02139 USA, http://www.cytel.com) was
used to compute statistics based on exact procedures.
Mann-Whitney test was used to calculate the difference in beta
cell mass between T2DM organ donors with and without e islet
antibodies or the DR3/DR4 class II allelic combination.
Results
Markedly Reduced Beta Cell Secretory Capacity in
clinically diagnosed T2DM subjects with Islet
Autoimmunity
The islet antibody positive group had significantly lower fasting C-
peptide and pro-insulin levels as compared to the antibody negative
groups (Table 1). Figure 1A shows the C-peptide levels during an
arginine test at variable glucose levels (150, 250 and 500 mg/dL)
according to previously established protocols [2]. These results
demonstrate the existence of poor beta cell secretion in the antibody
positive group for all time points. The antibody negative group on
insulin6metformin demonstrated a more impaired C-peptide
response to arginine when compared to the metformin only group.
Multiple comparison of AUC of serum C-peptide levels measured
during the arginine test at variable glucose levels (150, 250 and
500 mg/dL) confirmed a severe impairment of insulin secretion in
the antibody positive group as compared to both antibody negative
groups (p = 0.0001; p = 0.0001; p = 0.0001 respectively) (Figure 1B).
We then evaluated acute insulin responses to arginine (AIR)
after clamping plasma glucose at 120, 250 and 500 mg/dL [2].
The presence of islet antibodies correlated with severely impaired
b-cell function as demonstrated by a remarkably low AIRmax
compared to the antibody negative groups (either subjects on
insulin and/or metformin or metformin alone). For each group of
patients (antibody positive on insulin6metformin, antibody
negative on insulin6metformin and antibody negative on
metformin) AIR values for different glucose levels were statistically
significant (p = 0.012, 0.025, 0.015) respectively (Figure 1C).
These p values compare antibody positive vs. antibody negative
groups for all three glucose levels (120, 250 and 500 mg/dL).The
group on metformin only had the highest stimulated insulin
response at all glucose levels. Thus, these results demonstrate that
the presence of positive islet autoantibodies in patients with a
clinical diagnosis of type 2 diabetes identifies a group of patients
with poor beta cell function.
Markedly Diminished Beta Cell Mass in clinically
diagnosed T2DM subjects with Islet Autoimmunity or the
DR3/DR4 class II HLA allelic combination
Based on islet autoantibody testing and HLA genotyping
performed on cadaveric organ donors in whom a pre-mortem
Islet Autoimmunity in Clinical Diagnosed Type 2 Diabetes
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clinical diagnosis of T2DM was made, we defined the following
two groups of subjects: a) cadaveric donors with and without islet
antibodies; b) cadaveric donors with or without high-risk HLA
class II genotypes (Table 2). In particular, the first group consisted
of two GAD65 autoantibody positive subjects (with age of onset of
23.3 and 30.9 years) and the second group of two antibody
negative subjects carrying the T1DM high-risk alleles DR3/DR4
(with age of onset of 26.3 and 34.8 years). The definition of
Figure 1. Acute C-peptide and insulin response after arginine and glucose infusion. A. Comparison of C-peptide response as a function of
time and glucose/arginine stimulation for clinically diagnosed T2D patients antibody positive (insulin6metformin)(n = 7), antibody negative
(insulin6metformin) (n = 6) and antibody negative on metformin only (n = 5). Pulses of arginine were administered after clamping plasma glucose at
150, 250 and 500 mg/dL. B. The area under the curve (AUC) for C-peptide was calculated for the three groups. *p-value,0.0001 for antibody positive
vs. antibody negative groups for all three glucose levels. Error bars indicate SEM. C. Comparison of acute insulin response (AIR) to arginine at three
different plasma glucose levels (150, 250, 500 mg/dL) in antibody positive insulin therapy (n = 7), antibody negatives on insulin 6 metformin (n = 6)
and antibody negativesmetformin only (n = 5). *p-value,0.05 for antibody positive vs. antibody negative groups for all three glucose levels. Error bars
indicate SEM.
doi:10.1371/journal.pone.0106537.g001
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autoimmune diabetes in those subjects carrying the DR3/DR4
allele was based on the most recent ADA clinical practice
recommendations on the diagnosis and classification of diabetes
mellitus [30].
Quantification of beta cell mass in control donors revealed
average BCM of 0.47 gms (median = 0.33 gms, range = 0.07 to
2.09 gms), while in the T2DM group the mean beta cell mass was
0.26 gms (median = 0.26 gms, range 0 to 0.65 gms). Type 2
diabetic donors with surrogate markers of autoimmune diabetes
had reduced beta cell mass when compared to T2DM donors with
no evidence of autoimmune diabetes (P = 0.05) (Figure 2). There
was no significant difference in diabetes duration between these
two groups. Amongst the donors diagnosed with T2DM who had
autoimmune abnormalities (either islet autoantibodies or high-risk
HLA class II alleles), 4 out of 4 exhibited pattern A pathology
while among donors with T2DM and no evidence of autoimmune
diabetes, 3 out of 11 exhibited pattern B pathology (P = 0.026)
(Figure 3).
Insulin Resistance is present in clinically diagnosed T2DM
subjects with evidence for Islet Autoimmunity
These participants were also evaluated by a glucose clamp
study. Disposition index (DI), which is defined as the ratio of
insulin secretion over insulin sensitivity, was lower for the antibody
positive group as compared to the other two groups, consistent
with a defective beta cell function (p = 0.01 and 0.003 respectively)
(Figure S1A). Whole body insulin-mediated glucose uptake as
measured by the glucose infusion rate (GIR) was not significantly
different between the three groups (Figure S1B). There was a trend
towards higher adiponectin levels in the antibody positive group
(8819 vs 15877 mg/ml). No differences in CRP levels were
identified (Table 1).
It is known that there is a correlation between obesity, in
particular central obesity, and insulin resistance [31]. As expected
we found a negative correlation between BMI and GIR for the
antibody negative group (Figure 4). Similar findings were seen
when correlation between central fat and GIR was determined.
Interestingly the antibody positive group demonstrated no
correlation between GIR and BMI or GIR and central fat. These
findings imply that in clinically diagnosed type 2 diabetics with
autoantibodies against beta cells there is an obesity independent
factor leading to insulin resistance.
In terms of lipid profile, the HDL levels were higher in the
antibody positive group when compared to the antibody negative
on insulin6metformin (74 vs. 41 mg/dL). There was a trend
towards lower triglyceride levels in the antibody positive group (86
Figure 2. Beta cell mass determination. Beta cell mass (expressed as percentage of mean of donors without diabetes mellitus) in T2DM without
autoimmune markers [mean 67.706SEM 13.58 (n = 11) and T2DM with autoimmune markers (mean 12.806SEM 4.54 (n = 4)] (p = 0.05) Amongst the
donors with markers of autoimmune diabetes 4 out of 4 expressed pattern A pathology while among the donors without autoimmune markers, 3 out
of 11 expressed pattern B pathology (p = 0.026).
doi:10.1371/journal.pone.0106537.g002
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vs. 62 mg/dL). One subject in the antibody positive group had
significantly higher fasting triglyceride levels (163 mg/dL) while
the rest of the group had an average triglyceride level of 45 mg/dl
(Figure S2).
Discussion
The prevalence of both type 1 and type 2 diabetes has reached
epidemic proportions worldwide and the understanding of the role
of autoimmunity in diabetes has evolved along with the
characterization of new disease phenotypes [32]. While the
presence of autoantibodies directed to islet proteins is the hallmark
of ‘‘classical’’ T1DM, a number of studies have shown that
diabetes-related autoantibodies can be detected in 5–10% of
patients with other types of diabetes, such as type 2 diabetes, that
have not usually been associated with autoimmunity in their
etiology (5, 7, 8). This phenotype seems to be different than T1DM
in that the immunologic responses are mainly directed to GAD65
Ab and that there is a weaker association with HLA genotypes as
compared to classical T1DM [8,15]. A growing body of research
has documented the case of patients who are generally adults, non-
obese, who otherwise present a type-2 diabetes phenotype and
who puzzlingly also have circulating islet autoantibodies. These
characteristics have led to the term Latent Autoimmune Diabetes
of Adults (LADA) [22]. Currently, the diagnosis of LADA relies
primarily on the detection of autoantibodies against GAD65 in the
serum of clinically diagnosed T2DM patients. In this regard,
GAD65 testing provides the critical first identifier to detect this
unique diabetic disease phenotype [13,19,22,33]. Despite a wealth
of data supporting the role of genetic factors in T1DM and
T2DM, little is known regarding the genetics of LADA [22,34–
36]. Additionally, it has also been shown that, as is the case with
‘‘canonical’’ T1DM patients, LADA patients also possess T-cells
reactive to islet proteins [37].
In the present study we characterized a group of patients
clinically diagnosed as having T2DM with positive autoantibodies
against islet autoantigens. Measurement of b cell function through
arginine and glucose stimulation determined that these patients
exhibited a significant impairment of b cell function when
compared to a group of antibody negative of similar age, BMI
and time of diabetes diagnosis. Furthermore, unlike the antibody
negative group, patients with evidence of autoimmunity had
insulin resistance that was independent of BMI or central obesity.
Of note, previously reported observations indicate that psychoso-
cial factors influence the risk of autoimmune diabetes in adults,
possibly through mechanisms related to insulin resistance [38].
Hence, present compelling evidence to suggest that, despite high
BMI, subjects with diabetes and islet autoantibodies exhibit severe
Figure 3. Insulin and glucagon immunostaining. Immunohistochemical staining for insulin (Panel A and C) and glucagon (Panel B and D) in two
different islets from different area of the pancreas in a donor with T2DM and pattern A pancreatic pathology. The first islet (panel A and B) contains
both insulin and glucagon positive cells, while the second islet (Panel C and D) contains only glucagon positive cells.
doi:10.1371/journal.pone.0106537.g003
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beta cell dysfunction at baseline and in response to a potent insulin
secretagogue (arginine). This impaired beta cell function may be
caused by an autoimmune-mediated beta cell dysfunction/
destruction with a loss of beta cell mass.
Quantification of beta cell function through arginine/glucose
stimulation determined that as expected, individuals with a shorter
time since diagnosis of diabetes and that required no insulin have
relatively preserved beta cell function (metformin group only). This
study demonstrates that the antibody positive T2DM patients
exhibit a significant impaired beta cell function when compared to
the other two groups. As a matter of fact, the magnitude of AIRmax
is likely to decrease in those antibody positive diabetic patients
such as those clinically diagnosed T2DM patients with evidence of
islet cell autoimmunity described in this study.
A strength of the present work is that we evaluated all the
nPOD pancreatic tissue from T2DM organ donors available
through December 31, 2013 [25]; to the best of our knowledge,
this is the largest collection of pancreatic tissue from T2DM
cadaveric donors. However, a limitation of this study is a relatively
small sample size. The previously discussed in vivo observations
are reinforced by the analysis of pancreatic sections from T2DM
organ donors. In particular, we determined that a subset of organ
donors with T2DM showed pattern A pathology which is strongly
associated with autoimmune diabetes. Interestingly, these donors
were also positive for either islet autoantibodies or the autoim-
mune diabetes class II allelic combination DR3/DR4. The
presence of pattern A pathology in T2DM in association with
islet autoimmunity confirms that in subset of cases of T2DM, beta
cell dysfunction and loss may well be related to autoimmune
mechanisms [26]. It is not clear, at this stage, whether these
individuals have a mixed diabetes with immune-mediated beta cell
loss superimposed to other mechanisms causing insulin resistance
or whether immune mechanisms are responsible for both beta cell
loss and insulin resistance. In this small group, there was a
somewhat reduced beta cell mass in islet antibody and HLA DR3/
DR4 positive donors suggesting a more pronounced beta cell loss
in the presence of an autoimmune component to the disease.
Of note, a subanalysis from the ADOPT trial characterized
GAD Ab positive T2DM patients [39]. Unlike our findings, this
study suggested that GAD Ab positive and negative patients had
similar beta cell function. The discordance in findings could be
due to the fact that only patients that were drug naı¨ve for up to 3
years were included in the ADOPT trial and the analysis was
performed in early stages of the natural history of the disease,
whereas the LADA patients evaluated in this study were all on
insulin therapy and had at least a 5-year-duration of diabetes. In
Figure 4. Insulin sensitivity in the setting of islet autoimmunity. Correlation between insulin sensitivity (GIR) and obesity (BMI, central fat)
between all antibody negative (n = 11) and antibody positive on insulin6metformin (n = 7). Open squares indicate antibody negative on metformin
only while close squares indicate patients on insulin6metformin.
doi:10.1371/journal.pone.0106537.g004
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summary, we now present convincing evidence supporting that the
presence of islet cell autoantibodies in a T2DM population defines
a group of these subjects with significant impairment of beta cell
function and beta cell mass.
Studies have shown a strong relationship between diabetes and
inflammation [9,40–42]. Inflammation and dysregulated adipo-
kine secretion have been implicated in obesity-related insulin
resistance and type 2 diabetes. C-reactive protein (CRP) is one of
the most significant acute-phase proteins in humans and has been
associated with an increased risk in the development of diabetes
[43]. We previously reported [8] no significant difference in CRP
levels between antibody positive or antibody negative individuals
clinically diagnosed with T2DM. Adiponectin is regarded as an
anti-inflammatory adipokine and as such usually correlates
positively with insulin sensitivity. In T1DM adiponectin has been
described as higher than that of non-diabetics [44]. These
observations could not be explained by differences in age, gender
or fat distribution. We found a trend towards higher adiponectin
levels for the antibody positive group. This would support the
hypothesis that factors unrelated to adiponectin may contribute to
the development of insulin resistance in autoimmune diabetes.
The glucose clamp results revealed a good correlation between
BMI and GIR as well as central fat and GIR in the antibody
negative group. An interesting observation from this study is that
this correlation is lost for patients with evidence of autoantibodies.
These findings could suggest that a subgroup of patients,
previously estimated to be in the 5–10% range of T2DM, has
insulin resistance that is independent of obesity. Interestingly,
obesity independent insulin resistance has also been described as
present in type 1 diabetes [45]. It could be hypothesized that
glucotoxicity might be playing a role in the development of insulin
resistance in LADA. The overall glycemic control in our study was
relatively adequate and not significantly different between the
GAD65 Ab positive and negative groups as determined by HbA1c
suggesting that glucotoxicity was not an important factor. There is
gathering evidence to suggest that glucose variability may be
important in the development of insulin resistance [46]. We could
expect that significant beta cell dysfunction would be associated
with a higher degree of glucose variability. This glucose variability
has been associated with the development of oxidative stress and
higher levels of advanced glycation end products [47–49]. In
LADA these factors could be playing an important role in the
development of insulin resistance regardless of obesity. Defining
the impact of these mechanisms in the development of insulin
resistance in this particular population is key as these same factors
are involved in the development of a dysfunctional endothelium
leading to cardiovascular morbidity and mortality [50].
In summary, our study provides compelling evidence to suggest
a significant impairment of beta cell function and mass in clinically
diagnosed T2DM with evidence of islet autoimmunity. This
phenotype could be the end result of an immune-mediated beta
cell destruction. This particular subgroup of patients seems to
exhibit insulin resistance in a similar fashion of that of antibody
negative T2DM and independent of BMI or central obesity.
Routine islet autoantibody evaluation in all T2DM patients may
identify a subgroup of LADA with potentially robust responses to
immune therapy aimed at preserving insulin production and beta
cell mass in the early stages of the natural history of LADA.
Supporting Information
Figure S1 A. Disposition index measurements. Disposi-
tion Index (DI: b-cell compensation for insulin resistance) obtained
from the glucose clamp studies. p-value,0.05 for antibody
negative on metformin vs. antibody positive on insulin6metfor-
min. Horizontal bars indicate mean values. B. Comparison of
Glucose Infusion Rate (GIR) obtained during the glucose clamp
studies as measurement of insulin sensitivity. No significant
difference was found between groups.
(PPTX)
Figure S2 Triglyceride levels. Comparison of fasting triglyc-
eride levels between the clinically diagnosed T2D patients
antibody positive on insulin6metformin, antibody negative on
insulin6metformin and antibody negative on metformin. Hori-
zontal bars indicate mean values.
(PPT)
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